雜志介紹

Oncotargets And Therapy雜志介紹

《Oncotargets And Therapy》是一本以English為主的開(kāi)放獲取國(guó)際優(yōu)秀期刊，中文名稱腫瘤靶點(diǎn)和治療，本刊主要出版、報(bào)道醫(yī)學(xué)-BIOTECHNOLOGY & APPLIED MICROBIOLOGY領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為2.7，最新CiteScore 指數(shù)為9.7。

本刊近期中國(guó)學(xué)者發(fā)表的論文主要有：

• Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report

  Author: Zhang, Xiangming; Ni, Kai; Chen, Huijun

• Role of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer

  Author: Wang, Jia-Wei; Yuan, Qing; Li, Li; Cao, Kai-Hua; Liu, Qi; Wang, Hong-Liang; Hu, Ke; Wu, Xi; Wan, Jing-Hai

• Secondary Sinonasal Collision Tumor of Papillary Squamous Cell Carcinoma and Small Cell Neuroendocrine Carcinoma After Nasopharyngeal Carcinoma Radiotherapy: A Case Report and Literature Review of Sinonasal Collision Carcinomas

  Author: Tang, Hao; Wang, Lina; Xu, Wenfeng; Xu, Yujuan; Li, Xianyun; Guo, Deyu

• Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK-LIMS1 Fusion: A Case Report

  Author: Shi, Junmei; Jia, Zhaohui; Zhou, Zhiguo; Zhao, Liyan; Meng, Qingju; Liu, Yibing

英文介紹

Oncotargets And Therapy雜志英文介紹

OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents

-Novel therapeutic regimens for improved benefit and/or decreased side effects

-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.

-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.

-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.

-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Single nucleotide polymorphism (SNP) studies will not be considered.